Omeros Corporation (OMER) Tuesday announced positive data using OMS721, the lead human monoclonal antibody in Omeros' MASP-2 program, in a well-established animal model of thrombotic microangiopathy or TMA, a disorder that occurs in the microcirculation of the body's organs, most commonly the kidney and brain.
The company said it expects to submit a European Clinical Trial Application this quarter to initiate clinical trials evaluating OMS721. The lead indication planned for OMS721 clinical trials is atypical hemolytic uremic syndrome or aHUS, a rare but life-threatening form of TMA, added the firm.
Commenting on the development, Gregory Demopulos, CEO of Omeros said, "The current treatment options for aHUS are limited and, when compared to those options, we believe that OMS721 carries marked advantages that will translate to significant patient benefits. We are eager to evaluate the drug product in aHUS patients, and we remain on track to begin Phase 1 clinical trials mid-year."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.